title: Persistence and malignant sequelae of gestational trophoblastic disease: Clinical presentation, diagnosis, treatment and outcome.
abstract: BACKGROUND
  The major concern in gestational trophoblastic disease is management of persistent disease and malignant sequelae. However, prediction of response to treatment is difficult and methods used controversial.
  
  
  OBJECTIVE
  To evaluate the usefulness of clinical presentation, methods of diagnosis and categorisation of risk in determining clinical outcomes, by analysis of a database of 705 registered patients collected over 30 years.
  
  
  RESULTS
  From the database, there were 97 patients who developed persistent disease and malignant sequelae on the basis of defined criteria - 80.4% had molar pregnancy and 19.6% non-molar pregnancy. Vaginal bleeding was not a common presentation; 59.8% had no clinical symptoms. According to protocol, monitoring by serial human chorion gonadotrophin (HCG) levels followed by imaging screen was used in all patients; histology was also available in 41.2% from hysterectomy and curettage specimens. There were 16 of 76 patients with persisting disease who had metastases (21.1%), and 2 of 20 patients with choriocarcinoma who had an antecedent molar pregnancy (10.0%). Based on five risk factors, 25 patients were categorised as 'high risk' and assigned to receive multi-drug chemotherapy. There were two deaths (2.1% for all malignant sequelae); both were from molar pregnancies. One patient failed to respond and the other suffered a complication of intensive chemotherapy.
  
  
  CONCLUSIONS
  Serial HCG levels remain the best monitor to determine therapeutic response. Categorisation of 'high risk' by five factors is useful in treatment. Albeit a small series, clinical outcome is favourable with a five-year survival of 89.7%.
authors.affiliation: Betty Byrne Henderson Women's Health Research Centre, University of Queensland, Brisbane, Australia. si.khoo@uq.edu.au
authors.forename: Soo-Keat
authors.initials: SK
authors.lastname: Khoo
authors.forename: Mukhtiar
authors.initials: M
authors.lastname: Sidhu
authors.forename: David
authors.initials: D
authors.lastname: Baartz
authors.forename: Wai-Lum
authors.initials: WL
authors.lastname: Yip
authors.forename: Lee
authors.initials: L
authors.lastname: Tripcony
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D006063:Chorionic Gonadotropin / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D031901:Gestational Trophoblastic Disease / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007044:Hysterectomy; D009362:Neoplasm Metastasis; D011247:Pregnancy; D012189:Retrospective Studies; D018570:Risk Assessment; D016019:Survival Analysis
chemical_list: D006063:Chorionic Gonadotropin